These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38690124)

  • 21. First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia.
    Cheong HI; Yoo HW; Adachi M; Tanaka H; Fujiwara I; Hasegawa Y; Harada D; Sugimoto M; Okada Y; Kato M; Shimazaki R; Ozono K; Seino Y
    JBMR Plus; 2019 Feb; 3(2):e10074. PubMed ID: 30828689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy.
    Brener A; Lebenthal Y; Cleper R; Kapusta L; Zeitlin L
    Ther Adv Endocrinol Metab; 2021; 12():20420188211001150. PubMed ID: 33796255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
    Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
    J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia.
    Martín Ramos S; Gil-Calvo M; Roldán V; Castellano Martínez A; Santos F
    Front Pediatr; 2020; 8():48. PubMed ID: 32133333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab.
    Paloian NJ; Boyke-Lohmann LR; Steiner RD
    Front Pediatr; 2024; 12():1430921. PubMed ID: 39156019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia.
    Senoo S; Fujimoto M; Yamaguchi Y; Osaki M; Hanaki K; Namba N
    Clin Pediatr Endocrinol; 2024; 33(1):27-34. PubMed ID: 38299174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
    Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
    Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial.
    Fratzl-Zelman N; Hartmann MA; Gamsjaeger S; Rokidi S; Paschalis EP; Blouin S; Zwerina J
    J Bone Miner Res; 2022 Sep; 37(9):1665-1678. PubMed ID: 35775373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
    Brandi ML; Jan de Beur S; Briot K; Carpenter T; Cheong HI; Cohen-Solal M; Crowley RK; Eastell R; Imanishi Y; Imel EA; Ing SW; Insogna K; Ito N; Javaid K; Kamenicky P; Keen R; Kubota T; Lachmann RH; Perwad F; Pitukcheewanont P; Portale A; Ralston SH; Tanaka H; Weber TJ; Yoo HW; Sun W; Williams A; Nixon A; Takeuchi Y
    Calcif Tissue Int; 2022 Oct; 111(4):409-418. PubMed ID: 35927518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study.
    Michigami T; Kang HG; Namba N; Ito N; Kubota T; Shintani A; Kabata D; Kanematsu M; Nishida Y; Fukumoto S; Ozono K
    JBMR Plus; 2024 Aug; 8(8):ziae079. PubMed ID: 39015507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the Radiographic Global Impression of Change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH).
    Lim R; Shailam R; Hulett R; Skrinar A; Nixon A; Williams A; Nixon M; Thacher TD
    Bone; 2021 Jul; 148():115964. PubMed ID: 33878504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Burosumab and Dental Abscesses in Children With X-Linked Hypophosphatemia.
    Gadion M; Hervé A; Herrou J; Rothenbuhler A; Smail-Faugeron V; Courson F; Linglart A; Chaussain C; Biosse Duplan M
    JBMR Plus; 2022 Nov; 6(11):e10672. PubMed ID: 36398111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
    Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
    Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis.
    M Boot A; Ariceta G; Beck-Nielsen SS; Brandi ML; Briot K; Collantes CL; Giannini S; Haffner D; Keen R; Levtchenko E; Mughal MZ; Makitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Emma F
    Ther Adv Chronic Dis; 2024; 15():20406223241247643. PubMed ID: 38764445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score.
    Thacher TD; Pettifor JM; Tebben PJ; Creo AL; Skrinar A; Mao M; Chen CY; Chang T; San Martin J; Carpenter TO
    Bone; 2019 May; 122():76-81. PubMed ID: 30772600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study.
    Levy-Shraga Y; Levi S; Regev R; Gal S; Brener A; Lebenthal Y; Gillis D; Strich D; Zung A; Cleper R; Borovitz Y; Bello R; Tenenbaum A; Zadik Z; Davidovits M; Zeitlin L; Tiosano D
    Eur J Pediatr; 2023 Nov; 182(11):5191-5202. PubMed ID: 37707589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
    Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
    Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
    Filler G; Tremblay O; Chen E; Huang SSH; Stein R
    Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment.
    Kamenicky P; Briot K; Brandi ML; Cohen-Solal M; Crowley RK; Keen R; Kolta S; Lachmann RH; Lecoq AL; Ralston SH; Walsh JS; Rylands AJ; Williams A; Sun W; Nixon A; Nixon M; Javaid MK
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36854566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.